<DOC>
	<DOC>NCT01939184</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and efficacy of various fixed daily doses of WC3055 compared with placebo for the treatment of subjects with LUTS secondary to BPH.</brief_summary>
	<brief_title>Assess Safety &amp; Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<criteria>History of LUTS for ≥6 months secondary to BPH Total IPSS (International Prostate Symptom Score) ≥ 13 at Screening</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>